Blocking the HSF1 stress protein to fight cytomegalovirus
Targeting Nuclear HSF1 as a Novel Anti-HCMV Strategy
This research will try a drug that blocks the HSF1 protein to both stop cytomegalovirus from multiplying and help remove infected blood cells in people at risk, such as newborns and those with weakened immune systems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project ID | NIH-11283936 on NIH RePORTER |
What this research studies
Researchers are focusing on a protein called HSF1 that the virus uses to survive, and they are using a tool compound called DTHIB to block that protein. In lab experiments with infected cells, including monocytes and bone-marrow–derived cells, blocking HSF1 reduced viral replication and triggered death of latently infected cells. The team aims to develop a single treatment that both limits virus spread and eliminates cells that hide the virus. These are preclinical, laboratory-focused studies meant to lead to future treatments for people vulnerable to CMV.
Who could benefit from this research
Good fit: Ideal candidates for future trials would be people with active or latent CMV infection who are at high risk for complications, such as transplant recipients or other immunocompromised patients.
Not a fit: People without CMV infection, those whose infections are not driven by HSF1 activity, or individuals who cannot tolerate HSF1 inhibitors are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could both prevent CMV reactivation and reduce the reservoir of latently infected blood cells, lowering illness and the need for long-term antivirals.
How similar studies have performed: This is a novel strategy: early laboratory data using the HSF1 inhibitor DTHIB show promising effects in cells, but it has not yet been tested or proven in patients.
Where this research is happening
Syracuse, United States
- Upstate Medical University — Syracuse, United States (Active)
Researchers
- Principal investigator: Chan, Gary Ching Tao — Upstate Medical University
- Study coordinator: Chan, Gary Ching Tao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.